you everyone, for Welcome, and Ping. you, Thank us. joining thank
COVID-XX to a in new of first some made candidates. like exciting highlight have progress We I’d on New progress Year developing we’ve vaccine R&D the substantial initiatives. on with ushered
Coronavirus yet the continues disruptions and start year entering suffering. a We’re to the pandemic, into half worldwide and COVID-XX since to of nearly a cause
efforts, countries, are clear It’s able there’s efforts Although supply are significant U.S. products vaccination number develop hyper-productive the health still equity. critical it successful, is stop have vaccine there the there up to its as clear be drugs apparent needs is believe, this these CX hindering affordable get inequality. global efforts in of populations of vaccinated global bottlenecks our be many vaccines been to and We that growing to manufacturing and that vaccine efficient, the chains to it production save including more that to meet scientists spread becoming increasingly that platform suited protein are lives. demand and COVID-XX globally. to of to and ramp global and flexible is this for technology manufacture a do ways help ideally If
our on As have we’ve applying be that been vaccines such, development COVID-XX tirelessly speed more to CX the to and accessible. technology up affordable new the working of potential
protein-based our to produce COVID-XX large efficiently of several We leading demonstrate and studies and technology to and and believe from our safe in programs. COVID-XX the success products. effective human are scientists, multiple agencies, CX expedite cells reengineered animal partnerships to with government pharma worldwide rapidly companies quantities application We its partner stemmed our of pleased to
development. and We’ve research trial an are we preliminary and globally, Our first-in-human evaluated preclinical data, moving scientists industrial support its including to Research, academic, evaluated ZAPI. SARS-CoV-X-S-RBD contract safety governmental the now to organization Israel Based candidate, preclinical compelling studies as and anticipated CRXO vaccine Biological engaged by for been X animal efficacy. has and XX from Institute in DYAI-XXX manage on Phase clinical towards clinical the groups R&D and
stage it Moving program. the milestone for clinical major works and DYAI-XXX
to against an generation vaccines COVID-XX COVID-XX to with next a First, that endemic for and critical vaccine need this the distribution that the disease fight bridge population. still potency, risk the may significant and not become there’s But can it’s emphasize gap is global issues protecting over. for
as of variants. important And for may to COVID-XX solution an the proof-of-concept for Our global believe a next this emerging be generation affordable candidates clinical and trial vaccine furthermore, has serve DYAI-XXX DYAI-XXX more to highly with potent serve potential we need.
CX and valuable will beyond well for can the under conditions, for in CX be vaccine we has pharmaceutical clinical can is by and produce vaccine industry to CX produced well in DYAI-XXX anticipate number a a this itself. trial that although COVID-XX Second, its serves a humans, as accelerate for biologic Demonstrating our for and demonstrating that and platform by safely adoption, as the be use strong the a biotech and that. protein drug opportunities. globally, potential candidate, safe technology, of cGMP use commercialization proof-of-principle platform We the that de-risking humans, tolerated and it’s
end the the As year, mutate animal toxicology forward we following SARS-CoV-X bringing such, ongoing into our of different of Phase study. continues DYAI-XXX to look completion into X GLP the by variants. to
produce We monovalent antigens are CX additional vaccine lines and variant cell multivalent an candidates. SARS-CoV-X engineering to for
African, and already UK to protein have for levels towards RBD both will highly Brazilian full lead we We developing variants. stability, and successfully antigens potentially work at productivity continue additional antigen expressed and variant and the South spike
vaccines which efficacy even confer similar consequentially variants an that Importantly, appear be potential variants are semi-annual And the and is future may against it broader future here becoming seasonal require a approach new for efforts clear Multivalent have potentially expected emerging increasingly to flu, annual and managing COVID-XX to important shots. booster it is to annually, may and stay. variants pandemics. SARS-CoV-X or and
boosters Medytox SARS-CoV-X multivalent or immunize COVID-XX accelerate our with funded candidates to vaccine and this against partnership expanded we’ve the vaccine end, multiple our to development variants. development existing people fully of Towards future
of related highlighted productivity, to and and to recent in in realistic We potential most manufacturing vaccines develop affordable transformative CX cost larger if chat. firsthand key to understand in volumes. KOL was are The pleased challenges lower our Medytox multivalent fireside maybe rapidly CX speed to with technology partner manufacture solve the and cost to
health We potential provide on support, of and remain remarkable vaccine leaders to number thought discussion access website. listen challenges, have health COVID-XX to you test strongly the major is to a by to drugs encourage human advancing such our our on this replay the of advanced such parallel their grateful I watching are game and in on we as and In global panel all changing CX to for webinar, CX as COVID-XX and which initiatives, who to going available other animal team applications. a beyond. for are focused
TurtleTree number human of recombinant funded develop to growth and a an were During a challenge. Scientific to including we factors, scale the a at quarter, first with in pleased fully factors may large role affordable regenerative protein play has Manufacturing growth industry and enter development which cost been therapies. healing tissue into collaboration an critical
hurdle are acquire new overcome to technology this this in excited to opportunity. As CX commercial help our we such, significant
biotech of Our report solution. in largest for ongoing commercial CX better to to continue be interest. as These collaborations, for technology Jiangsu by manufacturing pharma sought with Hengrui such continues companies we cap, out biologic promising drugs company pharmaceutical results looking market other the many China a and by Medicine,
several conventional, antibody of We’re candidates particularly over promising monoclonal potential therapeutics. offer significant about the benefits antibodies for excited that bispecific
advancing antibodies, to towards drugs, these achieved clinical several these development. For and programs biologic other CX consistently of has high bispecific support productivity levels
to SBV health, results animal platform recombinant cell and animal protection cattle, virus are has cells the CX but evidently antigens antigen productivity in and hyper produced efforts next produce our Rift protection (NYSEARCA:SBV), safety, lines, Virus evaluating and February. efficacy both we CX studies ZAPI’s ZAPI Notably, from other demonstrated productivity, produced highlighted CX are of platform (RVFV). Stakeholders strong selected and cells Meeting for Valley the CX by expression virus. for leading greater pleased was antigens in in demonstrating the and mice SBV insect positive far at Fever from and of after sheep and As Final The antigen Schmallenberg
is RVFV funding from development as CX During ongoing research produced conduct quarter scale by are expanded as studies viability produce commercial These the using further Dyadic and SBV program of animal efforts antigens to its first additional to additional demonstrate providing CX. Is produce and potential by very optimize intended well studies to producing recombinant results the ZAPI the CX animal to have with nanoparticle larger to of ZAPI support vaccines nanoparticle cost. antigens. of at productivity quantities been studies subunit encouraging RVFV potential CX additional protein to CX vaccines. part use of further and expanded Preliminary program, SBV and conducting lower improve
to for an different successful a acute health potential a Additional two in from antigens CX vaccine of a production top with birds. is respiratory company collaboration for disease demonstrated animal produced
XXXX. initiate protection We expected provided by these animal June to study vaccine in evaluate of challenge candidates will an
to our access human development health opportunities these robust broad partnerships today TurtleTree, partnerships co-development Medytox large ZAPI, global highlighted Further such internal and Our and others drive and data the scientific in as animal that complements markets. provide efforts. growing commercial
R&D current continue more our CX produce efficiently the is affordable demonstrate based versatility As efforts and products. that protein of quantities rapidly large to to
position leaders flexible our to opinion and believe We experts as expect accessible more platform clear matter production. growing worldwide. production challenges a effective CX these companies for the partners, for will will leading address therapeutics solution of a number CX subject the seek commercial manufacturing with of our support scale cost growing advantages number and We coupled and and protein vaccines of key affordable platform
to Lucy to from our quarter, in of Lastly, biopharmaceutical wealth benefiting and We adoption of we during forward his the development, of first and Patrick Board the experience look industry. added lines cell commercialization Directors.
towards our As commercializing we work CX technology.
notably remainder to the our milestones, expect number to of we XXXX, ahead candidate achieve of first vaccine Looking DYAI-XXX. a
ready X animal the data, of After first an study year. our IND. We by last progressing expect this end the in initiated look GLP have to Phase human month, we X to Phase toxicology we our generating and submit trial to forward
impact applications. CX expect in and robust animal also continue that extensive to forward look our these to updating our that on diverse collaborations generate of potential We human broad health scientific of highlights you accomplishments. number We the data platform
need and we safe, scalable therapeutics and advance to the As for CX effective work continue meet to our rapid, global platform vaccines. to tirelessly
to employees, members affordable to population. global I With confidence for always, solutions our shareholders over for support times. for health thanks would I the financial these call their also more as As bringing work that, care I during turn challenging and will to thank continued commitment to update. my and want our towards our their like and Ping we partners extend dedication to our board
